Following various phone and smartwatch apps (Fitbits, fitness trackers, etc.), people have been focusing on taking 10,000 ...

Nirsevimab was effective in preventing RSV-associated ED encounters and hospitalisation among infants in their first RSV season, with greatest protection against hospitalisation. However, these ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that offered some respite after recent setbacks.

Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

A measles booster? The shingles shot? Here's expert advice on which shots you should get—and when.By Hallie LevineDiseases ...

Older adults hospitalized for respiratory syncytial virus (RSV) face an elevated risk of developing heart failure and a dangerous heart rhythm problem, a Canadian study found.